Trimetazidine inhibits cardiac fibrosis by reducing reactive oxygen species and downregulating connective tissue growth factor in streptozotocin-induced diabetic rats

Experimental and Therapeutic Medicine
Yunyue ZhaoJinlai Liu

Abstract

Diabetes may affect myocardial fibrosis through oxidative stress. Trimetazidine (TMZ) is an anti-anginal agent. The present study aimed to determine the modulatory effect of TMZ on reactive oxygen species (ROS) and connective tissue growth factor (CTGF) expression and to evaluate the potential of TMZ to improve diastolic function in streptozotocin (STZ)-induced diabetic rats. After treating STZ-induced diabetic rats with TMZ for 16 weeks, a decrease in malondialdehyde levels, cardiac collagen volume fraction, left ventricular (LV) end-diastolic pressure and protein expression of collagen-I (Col I), Col III and CTGF compared with those in diabetic control rats was observed. In vitro, TMZ inhibited Col I, Col III and CTGF protein expression in cardiac fibroblasts treated with high glucose and decreased intracellular ROS generation and hydroxyproline content in the cell culture medium of cardiac fibroblasts. TMZ markedly improved cardiac fibrosis and diastolic function in diabetic rats. This effect was associated with a reduction in ROS production and CTGF expression in cardiac fibroblasts. The present study suggests that TMZ may be beneficial for protecting the hearts of diabetic patients.

References

Dec 1, 1993·Journal of Cardiovascular Pharmacology·F M WilliamsT J Williams
Oct 1, 1996·Journal of Applied Physiology·K MatsumotoT Fushiki
Oct 23, 1997·Journal of Diabetes and Its Complications·M L MoriciA Lombardo
Feb 9, 2000·Acta Diabetologica·M KinalskiI Kinalska
Nov 20, 2002·Herz·Dinender KumarPawan K Singal
Dec 17, 2004·Journal of the American Society of Nephrology : JASN·Nadia Abdel WahabRoger M Mason
Jun 30, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Taher El-KadySherif Abdel-Hady
Jun 13, 2006·Japanese Journal of Ophthalmology·Satoshi MatsudaYasuo Tano
Sep 5, 2006·Journal of the American College of Cardiology·Gabriele FragassoAlberto Margonato
Nov 23, 2006·American Journal of Physiology. Heart and Circulatory Physiology·Julie H RennisonMargaret P Chandler
Feb 27, 2007·Translational Research : the Journal of Laboratory and Clinical Medicine·Yin RuixingRasheed Al-Ghazali
Apr 26, 2007·European Heart Journal·Romualdo BelardinelliAugusto Purcaro
Sep 29, 2007·Endocrinology·Manuela AragnoGiuseppe Boccuzzi
Jun 25, 2008·Journal of Cardiovascular Pharmacology·Romualdo BelardinelliFrancesca Lacalaprice
Sep 18, 2008·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Romualdo BelardinelliLoretta Volpe
Jul 25, 2009·American Journal of Physiology. Cell Physiology·Xiaoyu WangStephen M Twigg
Aug 27, 2009·American Journal of Physiology. Endocrinology and Metabolism·Patricia E ShamhartJ Gary Meszaros
Jul 17, 2010·Journal of Cellular Physiology·Guido KrenningRaghu Kalluri
Feb 28, 2013·Heart Failure Reviews·Michael IsfortLoren E Wold
Oct 11, 2013·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Bin DaiHong Zhang

❮ Previous
Next ❯

Citations

Feb 7, 2020·International Journal of Molecular Sciences·Scott P Levick, Alexander Widiapradja
Feb 19, 2021·Frontiers in Pharmacology·Hongyang ShuDao Wen Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.